Simulations Plus, Inc. · NASDAQ:SLP
Simulations Plus — BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference 2021
20 slides from Simulations Plus's conference presentation, Feb 18, 2021
Slide 1: BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
(NASDAQ:SLP) BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference February 18, 2021
Slide 2: Safe Harbor Statement
Safe Harbor Statement With the exception of historical information, the matters discussed in this presentation are forward-looking statements that involve a number of risks and uncertainties. The actual results of the Company could differ significantly from those statements. Factors that could cause
Slide 3: Company Overview
Company Overview ❑ Industry-leading provider of modeling and simulation solutions used by major pharmaceutical, biotech, chemical, consumer goods companies and regulatory agencies worldwide ❑ Innovative software and services to improve drug development from discovery to regulatory approval with supp
Slide 4: Our Value Proposition
Our Value Proposition Avg. cost of $1.4B and 10+ years to bring a drug to market 1,2 • Our solutions allow customers to model and predict results of chemical and biological tests required in the R&D process to improve success rates at multiple points in the process: − Computational AI models help sc
Slide 5: We Improve Drug Discovery and Development
We Improve Drug Discovery and Development MedChem Designer ADMET Predictor GastroPlus DDDPlus MembranePlus Preclinical Regulatory Discovery Clinical Studies Development Approval Monolix DILIsym RENAsym NAFLDsym Consulting Services 5
Slide 6: PKPD Software Solutions
PKPD Software Solutions Population PKPD Model to support dose regimen, risk exposure, Monolix clinical trial protocol design and analysis, drug label specifications Suite and regulatory submission Datxplore Exploration and visualization of data PKanalix Non-compartmental and compartmental analysis M
Slide 7: QSP/QST Software Solutions
QSP/QST Software Solutions Determine potential drug-induced liver injury hazard posed by DILIsym individual drug candidates to support clinical trial optimization Assess the potential for drug-induced kidney injury of drug candidates RENAsym to support clinical trial optimization and clinical trial
Slide 8: PBPK Software Solutions and AI Data Mining
PBPK Software Solutions and AI Data Mining Simulating IV, oral, oral cavity, ocular, inhalation, skin and IM GastroPlus absorption, PBPK, PBBM, PD modeling and drug-drug interactions QSAR modeling enabling rapid prediction of 140+ ADMET properties ADMET Used for lead generation and optimization Pred
Slide 9: Services Solutions
Services Solutions • 70+ scientific PhD experts provide insightful solutions to improve the productivity of science-based drug development • Focusing on lead selection, pharmacology, ADMET and DMPK, dose regimen, efficacy and safety • Capabilities include: − Population PKPD data assembly, modeling,
Slide 10: Janssen Case Study: Accelerating Regulatory Interactions
Janssen Case Study: Accelerating Regulatory Interactions Virtual crossover trials to establish drug product specification after manufacturing changes • Janssen changed the manufacturing process to improve efficiencies with scale-up techniques post approval • FDA requested clinical study to confirm b
Slide 11: Client Case Study: Strategic Use of Modeling & Simulation
Client Case Study: Strategic Use of Modeling & Simulation In Silico Methods Improve the Probability of Phase 3 Success • Client with novel antibody for prophylactic use in competitive migraine market had Phase 3 development plan with predicted probability of success of <15% • Iteratively developed m
Slide 12: Revenue Growth Drivers
Revenue Growth Drivers Increasing acceptance of modeling and simulation by FDA and drug industry High customer satisfaction with ~95% software contract renewal rate (by fees) Recently improved and expanded sales infrastructure 19%+ Increasing opportunities for product and Revenue CAGR service cross-
Slide 13: Consistent Year-over-Year Revenue Performance
Consistent Year-over-Year Revenue Performance (in millions) 22% Growth $41.6 19% CAGR $34.0 $29.7 $20.0 $15.5 $24.1 $12.7 $9.2 $21.6 $17.0 $18.5 $14.9 FY17 FY18 FY19 FY20 Software Services 13
Slide 14: FY20 Software and Services Mix
FY20 Software and Services Mix Software Products % of Services Offerings % of Total Revenues Total Revenues GastroPlus 34% PKPD 23% ADMET QSP/ 10% 15% Predictor QST Monolix Suite* 4% PBPK 10% Other Software 4% 14
Slide 15: Strategic Opportunities for Expansion and Growth
Strategic Opportunities for Expansion and Growth • Expand product offerings through opportunistic acquisitions − Fill gaps in the current product offerings − Focus on immediately or near-term accretive opportunities − Fragmented industry amenable to consolidation • Further expand global sales reach
Slide 16: Q1 FY21 Performance & FY21 Full Year Outlook
Q1 FY21 Performance & FY21 Full Year Outlook • Total Revenue Growth − Q1 performance: 14% y/y growth − Full-year target range: 15-20% y/y organic growth plus 3-5% from Lixoft • Software Revenue Growth − Q1 performance: 35% y/y growth − Full-year target range: 20-25% y/y growth • Services Revenue Gro
Slide 17: Investment Highlights
Investment Highlights • Provider of innovative modeling and simulation software and consulting services focused on pharmaceutical and biotechnology companies − Solutions from early discovery through regulatory approval • Pure play in the in silico drug discovery space • Growing acceptance of technol
Slide 18: Financial Summary and Selected Financial Information
Financial Summary and Selected Financial Information Nasdaq SLP Q1 Cash and short-term investments $119M Q1 Borrowed Debt Outstanding $0 Market Capitalization (a/o 2/10/21) $1.6B Q1 Fully Diluted Shares Out 20.8M 30-Day Average Daily Trading Volume ~225K (a/o 2/10/21) 18
Slide 19: Thank you!
Thank you! https://www.simulations-plus.com
Slide 20: References
References 1. J Health Econ. 2016 May;47:20-33. 2. Brochure: “Biopharmaceutical Research & Development: The Process Behind New Medicines”. PhRMA. 3. EvaluatePharma® World Preview 2017, Outlook to 2022, 10th Edition, June 2017, p. 19.